Alnylam Pharmaceuticals Inc. announced the pricing of a private offering of $575 million aggregate principal amount of convertible senior notes due 2028, increased from an initial offering of $500 million. The notes will not bear regular interest and will mature on September 15, 2028. Net proceeds from the offering are estimated to be approximately $561.6 million. Alnylam plans to use a portion of the proceeds to pay for capped call transactions and the remainder, along with cash on hand, to repurchase $637.8 million aggregate principal amount of existing notes due 2027 through privately negotiated transactions. The offering is expected to close on September 12, 2025.

Read more at Nasdaq: Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028